John Connolly

John Connolly, PhD, is a senior principal investigator and director for translational immunology at the Institute of Molecular and Cellular Biology (IMCB) A*Star. He is also the Chief Scientific Officer (CSO) at the Parker Institute for Cancer Immunotherapy.

He previously served as CSO of Tessa Therapeutics, a clinical stage cell therapy company focused on solid tumor immunotherapy, where he led a team of researchers to develop next-generation T cell therapy treatments. Dr. Connolly is also an associate professor at National University of Singapore and an adjunct associate professor of Immunology at Baylor University, where he served on the Board of Governors for the Institute of Biomedical Sciences.

Dr. Connolly has more than 20 years of research experience in immunotherapy and has published more than 100 papers and chapters in peer-reviewed journals. As a human immunologist, his research interests focus on immune monitoring and immunometabolism. He received his PhD in Immunology from Dartmouth Medical School, where he studied human dendritic cell biology.